EMA Application withdrawn: Clopidogrel Teva Pharma (clopidogrel) — Teva Pharma B.V.

View source ↗

Summary

The EMA application for Clopidogrel Teva Pharma (clopidogrel) has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Syndrome
• Myocardial Infarction
• Peripheral Vascular Disease
• Transient Ischemic Attack

Drugs mentioned

• CLOPIDOGREL (CLOPIDOGREL)

Snippet

Status: Application withdrawn. Therapeutic area: Ischemic Attack, Transient;Peripheral Vascular Diseases;Myocardial Infarction;Acute Coronary Syndrome. MAH: Teva Pharma B.V.. Decision date: 31/12/2009